3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Carcinoma, Non-Small-Cell Lung
21
Lung Neoplasms
7
Adenocarcinoma of Lung
7
Neoplasm Metastasis
4
Carcinoma
3
cMET-dysregulated Advanced Solid Tumors
2
Melanoma
2
Glioblastoma
2
cMET Dysegulation Advanced Solid Tumors
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Laryngeal Diseases
1
Hepatic Impairment
1
Gliosarcoma
1
EGFR-mutant Non-small Cell Lung Cancer
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Bronchial Neoplasms
1
Brain Neoplasms
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
166
Nivolumab
111
Ipilimumab
93
Dacarbazine
44
trametinib
36
dabrafenib
34
Vemurafenib
33
binimetinib
23
atezolizumab
23
Temozolomide
21
cemiplimab
18
Paclitaxel
18
encorafenib
17
spartalizumab
16
cobimetinib
15
Carboplatin
14
talimogene laherparepvec
13
Cisplatin
13
Cyclophosphamide
12
lenvatinib
10
Pemetrexed
10
Gemcitabine
10
Docetaxel
10
durvalumab
9
Drug Therapy
9
Bevacizumab
9
tremelimumab
8
Injections
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Melanoma
×
capmatinib
×
Clear all
NCT03484923
2024-06-18
PLATforM
Novartis
Phase 2
Completed
196 enrolled
22 charts
NCT02159066
2024-03-05
LOGIC-2
Pfizer
Phase 2
Completed
158 enrolled
40 charts